Risk factors for composite endpoint
| Variable (univariate analysis) | HR (95% CI) | p Value |
|---|---|---|
| Age at MELD-XI score (years) | 0.69 | |
| ≤18 (n=23) | 1.00 | |
| 19–23 (n=24) | 1.62 (0.39 to 6.67) | |
| 24–31 (n=25) | 2.1 (0.52 to 8.25) | |
| ≥32 (n=24) | 2.2 (0.56 to 8.66) | |
| Systemic ventricle | 0.54 | |
| Morphologically right (n=18) | 1.00 | |
| Morphologically left (n=67) | 1.61 (0.38 to 6.81) | |
| Biventricular (n=11) | 2.53 (0.69 to 9.35) | |
| PLE (n=10) | 0.52 (0.07 to 3.97) | 0.91 |
| Pulmonary arterial thrombosis/embolism (n=2) | 1.26 (0.15 to 10.23) | 0.83 |
| Thrombus within Fontan (n=23) | 1.53 (0.53 to 4.4) | 0.43 |
| Number of MELD-XI measurements | 0.84 | |
| 1 (n=17) | 1.00 | |
| 2 (n=79) | 1.79 (0.21 to 15.3) | |
| 3 (n=43) | 2.35 (0.28 to 20.02) | |
| 4 (n=21) | 2.38 (0.28 to 20.56) | |
| Therapy with warfarin/ASA (n=89) | 0.21 (0.06 to 0.76) | 0.02 |
| Therapy with diuretics (n=55) | 12.89 (1.72 to 96.88) | 0.01 |
| Creatinine | 0.001 | |
| <2 mg/dl (n=89) | 1.00 | |
| ≥2 mg/dl (n=7) | 8.21 (2.84 to 23.78) | |
| Total bilirubin | 0.22 | |
| 1.0–1.3 mg/dl (n=63) | 1.00 | |
| 1.4–2.3 mg/dl (n=22) | 0.44 (0.1 to 1.99) | |
| 2.4–10.3 mg/dl (n=11) | 2.11 (0.59 to 7.51) | |
| MELD-XI | 0.006 | |
| <11 (n=47) | 1.00 | |
| 11–18 (n=38) | 2.42 (0.78 to 7.46) | |
| >18 (n=11) | 8.98 (2.53 to 31.85) | |
| Variable (multivariate analysis) | HR (95% CI) | p value |
| Therapy with warfarin/ASA (n=89) | 0.2 (0.05 to 0.78) | 0.02 |
| Therapy with diuretics (n=55) | 9.16 (1.19 to 70.36) | 0.03 |
| Time since Fontan (per 1 year increase) | 1.07 (1.00 to 1.15) | 0.05 |
| MELD-XI | 0.008 | |
| <11 (n=47) | 1.00 | |
| 11–18 (n=38) | 1.76 (0.51 to 6.13) | |
| >18 (n=11) | 7.76 (2.05 to 29.33) |
MELD-XI, Model for End-stage Liver disease eXcluding INR; PLE, protein-losing enteropathy, ASA; Aspririn.